Cessatech A/S (8GN.F)

0.8180 -0.0080 (-0.97%) As of 09:15AM CEST. Market open.

Cessatech A/S

Kanonbådsvej 2
Copenhagen 1437
Denmark
45 93 87 23 09
https://www.cessatech.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 4

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jes Trygved	Chief Executive Officer	N/A	N/A	1973
Martin Juhl	Chief Scientific Officer and Head of CMC, Device Development & Operations	N/A	N/A	N/A
Louise Bak	Head of Regulatory Affairs	N/A	N/A	N/A
Malene Cording	Head of Clinical Development & Operations	N/A	N/A	N/A
Mai Brigsted Gregersen	Head of Quality Assurance	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Cessatech A/S engages in identifying and developing drugs for the treatment of medical unmet need in children in Denmark. The company's lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for magnetic resonance imaging scanning; and CT003, a local anesthetic gel. The company has a collaboration and license agreement with Ventis Pharma Corporation to develop and formulate pain management therapies. Cessatech A/S was incorporated in 2020 and is based in Copenhagen, Denmark.

Corporate governance

Cessatech A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.